Trials / Completed
CompletedNCT02105636
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 361 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | |
| DRUG | Cetuximab | |
| DRUG | Methotrexate | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2014-05-29
- Primary completion
- 2015-11-06
- Completion
- 2021-09-10
- First posted
- 2014-04-07
- Last updated
- 2022-10-05
- Results posted
- 2017-01-11
Locations
64 sites across 15 countries: United States, Argentina, Brazil, Canada, France, Germany, Hong Kong, Italy, Japan, Netherlands, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02105636. Inclusion in this directory is not an endorsement.